Press Releases
2026
Freenome Reports Top-Line Readout of Updated SimpleScreen™ CRC Colorectal Cancer Screening Blood Test Met All Primary and Secondary Endpoints
– Updated test version achieved significant performance improvement in detecting advanced precancerous lesions, including those with high-grade dysplasia – Modeling projects the improvements would translate ...
Perceptive Capital Solutions Corp and Freenome Announce Effectiveness of Registration Statement for Proposed Business Combination
– Extraordinary General Meeting of Perceptive Shareholders Scheduled for July 9, 2026 NEW YORK and BRISBANE, Calif., June 18, 2026 /PRNewswire/ — Perceptive Capital Solutions Corp (“PCSC”) ...
Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
– Collaboration is designed to improve analytical speed and accuracy of Freenome’s blood-based cancer screening tests – Brisbane, CA (Jan. 12, 2026) — Freenome today ...
Freenome Delivers Improved Performance in Its Colorectal Cancer Blood Test with Sensitivity of 85% for CRC and 22% for Advanced Precancerous Lesions
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with ...
2025
Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform
– Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital – – Freenome stockholders, ...
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.
– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially worth $200+ million increases Roche’s ...
Freenome Appoints Industry Veteran Rob Guigley as Chief Commercial Officer to Drive Commercial Strategy, As Agreement with Exact Sciences Clears Antitrust Review
– Freenome is building commercial infrastructure following recent CLIA lab certification and early access program for key health system partners, with new test launches for ...
Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company’s Next Chapter of Commercial Growth and Product Innovation
Accomplished industry leader brings specialized experience to advance Freenome’s screening blood tests for colorectal cancer, lung cancer and additional indications Brisbane, CA (April 8, 2025) ...
2024
Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer
Study met all primary endpoints, including 79.2% sensitivity for colorectal cancer (CRC) and 91.5% specificity for non-advanced colorectal neoplasia PREEMPT CRC, the largest study of ...